DiaMedica Therapeutics Inc.
DMAC
$5.67
-$0.13-2.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.90M | 1.71M | 2.07M | 2.17M | 1.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.88M | 5.64M | 5.74M | 5.85M | 5.16M |
| Operating Income | -6.88M | -5.64M | -5.74M | -5.85M | -5.16M |
| Income Before Tax | -6.27M | -5.11M | -5.14M | -5.14M | -4.46M |
| Income Tax Expenses | 7.00K | 7.00K | 7.00K | 22.00K | 7.00K |
| Earnings from Continuing Operations | -6.27M | -5.12M | -5.15M | -5.16M | -4.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.27M | -5.12M | -5.15M | -5.16M | -4.47M |
| EBIT | -6.88M | -5.64M | -5.74M | -5.85M | -5.16M |
| EBITDA | -6.87M | -5.63M | -5.73M | -5.84M | -5.15M |
| EPS Basic | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.08 | -0.08 | -0.07 |
| EPS Diluted | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.08 | -0.08 | -0.07 |
| Average Basic Shares Outstanding | 42.75M | 38.07M | 37.96M | 38.01M | 37.95M |
| Average Diluted Shares Outstanding | 42.75M | 38.07M | 37.96M | 38.01M | 37.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
